血管紧张素受体脑啡肽酶抑制剂（ARNi）：一类新型药物的临床研究
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
作者信息
Gori Mauro, Volterrani Maurizio, Piepoli Massimo, Senni Michele
机构信息
Cardiology, Heart Failure and Heart Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Cardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy.
出版信息
Int J Cardiol. 2017 Jan 1;226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.
Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
沙库巴曲缬沙坦（恩格列净，诺华公司，仍常被称为LCZ696）是一种复方药物，被描述为一类新型的双重作用血管紧张素受体脑啡肽酶抑制剂（ARNi）。这种复方药物已在射血分数保留的心力衰竭（HFpEF）和射血分数降低的心力衰竭（HFrEF）患者中进行了成功研究。在本综述中，总结了HFpEF和HFrEF患者的证据，包括最新研究的结果。
Zotero 插件